Biotechnology Jobs

• Zug, Switzerland
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of early clinical development medical directors and clinical scientists, owning Phase I/II clinical development plans including first-in-human, dose-escalation and proof-of-concept studies in lung and head/neck cancers. Bridges preclinical discovery and clinical development, driving translational and biomarker strategy with cross-functional and regulatory partners.

AI/ML

• London
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, translational and biomarker strategy, and regulatory submissions across a lung and head/neck cancer portfolio.

AI/ML

• Grimsby
• US$188,100 – US$313,500 pa
• Director

Leads quantitative systems pharmacology and QST modelling within a clinical pharmacology and quantitative medicine group, building mechanistic models of disease and drug action and running simulations to inform trial design. Defines and coordinates MIDD strategies across respiratory, immunology and inflammation programmes, working with biologists, clinicians, pharmacometricians and statisticians. Combines inverse-problem modelling, scientific ML and statistical methods to support decisions from exploratory research through clinical development.

• USA - Pennsylvania - Upper Providence
• US$188,100 – US$313,500 pa
• Director

Leads quantitative systems pharmacology and QST modelling within a clinical pharmacology and quantitative medicine group, building mechanistic mathematical models of disease and drug action to inform trial design and MIDD strategy. Collaborates with biologists, clinicians, pharmacometricians and AI/ML teams, and represents the function on internal advisory boards.

• London
• Hybrid
• US$188,100 – US$313,500 pa
• Director
• Permanent

Leads quantitative systems pharmacology and QST modelling within a clinical pharmacology and quantitative medicine group, building mechanistic models of disease and drug action and running simulations to inform trial design. Defines and coordinates MIDD strategies across respiratory, immunology and inflammation programmes, working with biologists, clinicians, pharmacometricians and AI/ML specialists. The role sits in a newly formed centre of excellence and involves representing QSP on internal advisory boards.

• Durham Blackwell Street
• US$188,100 – US$313,500 pa
• Director

Leads quantitative systems pharmacology and QST modelling within a clinical pharmacology and quantitative medicine group, building mechanistic models of disease and drug action and running simulations to assess trial design. Defines and coordinates MIDD strategies across respiratory, immunology and inflammation programmes, working with biologists, clinicians, pharmacometricians and AI/ML specialists. The role sits in a newly established Centre of Excellence for model-informed drug development.

• Waltham, United States
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and launch. Sets disease-area strategy, chairs governance forums and scientific advisory boards, and line-manages clinical development leads and medical directors within a global matrix team.

AI/ML

• Stevenage
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and launch. Provides portfolio oversight, chairs governance forums and scientific advisory boards, and line-manages Clinical Development Leads and Medical Directors within a global matrix team.

AI/ML

• London
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development strategy for a hematology oncology portfolio, from first-in-human studies through registrational trials, regulatory approval and initial launch. Provides program oversight at governance forums, co-leads asset development with matrix partners, and line-manages Clinical Development Leads, Medical Directors and Clinical Scientists. Champions novel approaches such as AI/ML, innovative trial designs and real-world data.

AI/ML

• Upper Providence
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, approval and launch. Sets disease-area strategy, chairs governance forums and advisory boards, and line-manages clinical development leads within a global matrix. Distinct for its portfolio-level enterprise scope and hybrid US/UK/Swiss base.

AI/ML

• Baar Onyx
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and initial launch. Chairs governance forums, co-leads matrix asset teams and line-manages clinical development leads, medical directors and clinical scientists. Distinct for its portfolio-level scope across early- and late-phase programs and its cross-functional connector role spanning research, translational medicine and commercial strategy.

AI/ML

• Stevenage
• Hybrid · 2 days in office
• US$242,250 – US$403,750 pa
• Director

Accountable for end-to-end clinical development of a multi-tumor oncology asset, from first-in-human through registrational trials, regulatory approval and initial market launch. Acts as senior clinical representative at governance forums and leads cross-functional, matrixed teams spanning research, precision medicine, medical affairs and commercial. Requires deep antibody-drug conjugate and global health authority experience.

AI/ML

• Waltham, United States
• Hybrid · 2 days in office
• US$242,250 – US$403,750 pa
• Director · manages people

Accountable for end-to-end clinical development strategy for a multi-tumor oncology asset, spanning first-in-human through registrational trials, regulatory approval and initial launch. Acts as senior clinical representative at governance forums and leads cross-functional collaboration across research, precision medicine, medical affairs and commercial in a global matrix.

AI/ML

• Zug, Switzerland
• Hybrid · 2 days in office
• US$242,250 – US$403,750 pa
• Director · manages people

Accountable for end-to-end clinical development of a multi-tumor oncology asset, from first-in-human through registrational trials, regulatory approval and launch. Leads cross-functional strategy with research, precision medicine, medical affairs and commercial partners, and represents the program at senior governance forums. Requires deep antibody-drug conjugate and global regulatory experience.

• London
• Hybrid · 2 days in office
• US$242,250 – US$403,750 pa
• Director · manages people

Accountable for end-to-end clinical development strategy for a multi-tumor oncology asset, spanning first-in-human through registrational trials, regulatory filing and initial market launch. Acts as senior clinical representative at governance forums and leads cross-functional, matrixed teams across research, precision medicine, medical affairs and commercial. Requires deep antibody-drug conjugate and global health authority experience.